Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility

Biochemical and Biophysical Research Communications

Volumn 419, Issue 2, 2012, Pages 274-280

  Lu, Renquan ^a,b   Sun, Xinghui ^c,d   Xiao, Ran ^a   Zhou, Lei ^a   Gao, Xiang ^a   Guo, Lin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Human epididymis protein 4; MAPK signaling pathway; Ovarian neoplasm; RNA interference

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SPREADING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84862809311     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.008     Document Type: Article

References (28)

1. Schummer M., Ng W.V., Bumgarner R.E., et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238:375-385.
2. Hellstrom I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63:3695-3700.
3. Drapkin R., von Horsten H.H., Lin Y., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is over-expressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65:2162-2169.
4. Lu R.Q., Hu J., Guo L. Studies on the value of human epididymis protein 4 in patients with ovarian cancer. Chin. J. Lab. Med. 2009, 1379-1383.
5. Kassis J., Lauffenburger D.A., Turner T., et al. Tumor invasion as dysregulated cell motility. Semin. Cancer Biol. 2001, 11:105-117.
6. Yamazaki D., Kurisu S., Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005, 96:379-386.
7. Lu R.Q., Hu J., Guo L., et al. Construction, expression of HE4 fusion protein and its identification. Chin. J. Lab. Diag. 2010, 32:17-19.
8. Lu R.Q., Sun M., Feng J.J., et al. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer 2011, 11:270-280.
9. Hu B., Kong L.L., Matthews R.T., et al. The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J. Biol. Chem. 2008, 283:24848-24859.
10. Johnson G.L. Signal transduction abnormalities in cancer mitogen-activated protein kinase regulation is altered in breast cancer. J. Clin. Invest. 1997, 99:1463-1464.
11. Lowe T., Ferrell B., Leong L. Quality-of-life issues in the management of epithelial ovarian cancer. Curr. Treat Options Oncol. 2007, 8:402-416.
12. Feki A., Berardi P., Bellingan G., et al. Dissemination of intraperitoneal ovarian cancer: discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Crit. Rev. Oncol. Hematol. 2009, 72:1-9.
13. Moore R.G., Jabre-Raughley M., Brown A.K., et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am. J. Obstet. Gynecol. 2010, 203. 228 e1-6.
14. Tauchi K., Kakudo K., Machimura T., et al. Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer 1991, 67:3042-3050.
15. Inufusa H., Nakatani Y., Adachi T., et al. Correlation of prognosis of breast cancer patients and expression of ley which acts as a cofactor of tumor procoagulant. Int. J. Oncol. 1998, 13:481-487.
16. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1176-1181.
17. Yan L.M., Lin B., Zhu L.C., et al. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5 beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie 2010, 92:852-857.
18. Iwamori M. A new turning point in glycosphingolipid research. Hum. Cell 2005, 18:117-133.
19. Roseman S. Reflections on glycobiology. J. Biol. Chem. 2001, 276:41527-41542.
20. Farber E. The multistep nature of cancer development. Cancer Res. 1984, 44:4217-4223.
21. Kirchhoff C., Habben I., Ivell R., et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 1991, 45:350-357.
22. Kiechle M., Jacobsen A., Schwarz-Boeger U., et al. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001, 91:534-540.
23. Devoogdt N., Revets H., Ghassabeh G.H., et al. Secretory leukocyte protease inhibitor in cancer development. Ann. N. Y. Acad. Sci. 2004, 1028:380-389.
24. Zhang D., Simmen R.C., Michel F.J., et al. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J. Biol. Chem. 2002, 277:29999-30009.
25. Li Y., Sarkar F.H. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J. Nutr. 2002, 132:3623-3631.
26. Ning Y., Zeineldin R., Liu Y., et al. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res. 2005, 65:9280-9286.
27. Zou S.L., Chang X.H., Ye X., et al. Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer. Chin. Med. J. 2011, 124:3133-3140.
28. Eblen S.T., Slack-Davis J.K., Tarcsafalvi A., et al. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol. Cell Biol. 2004, 24:2308-2317.